TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04131179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)
Description: Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness.
Study: NCT04574401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-002
Description: Intravenous injection of IS-002 Investigational Drug
Study: NCT03372967

Intervention type: BIOLOGICAL
Intervention: Vaccine administration by a pharmacist
Description: Administration, number and types, of vaccines by a pharmacist

Intervention type: BEHAVIORAL
Intervention: Unmet vaccination needs identified and met
Description: Identification of unmet vaccination needs and having those needs met

Intervention type: BEHAVIORAL
Intervention: Vaccination forecast review and patient education
Description: Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
Study: NCT04037579

Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey

Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey

Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey

Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey
Study: NCT01602289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Administered orally
Study: NCT02076282

Intervention type: OTHER
Intervention: 1 MRI scan
Description: For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast

Intervention type: OTHER
Intervention: 1 MRI scan
Description: For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast
Study: NCT02960607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
Study: NCT03346122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 6
Description: Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 7
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 8
Description: Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 9
Description: Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
Study: NCT01812928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study: NCT04376034

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma 1 Unit
Description: Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma 2 Units
Description: Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
Study: NCT01215968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: 1.5 mg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT03250728

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood puncture
Description: Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood puncture
Description: Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system
Study: NCT02155816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 7 + 3
Description: Ingestion of omega 7 + 3 daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega 3 daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium chain triglycerides
Study: NCT01566747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg day to be given continuously until disease progression.
Study: NCT00118872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGG yogurt
Description: Lactobacillus GG containing yogurt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo yogurt
Description: Yogurt NOT containing the active LGG bacteria
Study: NCT00960492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
Study: NCT04464434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront autologous HSCT
Description: HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg.
Study: NCT02692755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole or Fulvestrant
Description: Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
Study: NCT03387020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04236362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor
Study: NCT02770924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA TRI TORIC
Description: phacoemulsification with IOL implantation
Study: NCT03651791

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: USPIO labeled MSC injection
Description: USPIO labeled MSC injection
Study: NCT02774681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02770924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA TRI
Description: phacoemulsification with IOL implantation
Study: NCT02774681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT02282696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire, focus group participation
Description: participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
Study: NCT03221985

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: questionnaire with application on smartphone
Study: NCT01242657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Module
Description: Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Not On Tobacco (N-O-T) Program
Description: Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
Study: NCT00321451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: 4 biweekly outpatient sessions with sleep psychologist
Study: NCT01242657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not On Tobacco (N-O-T) Program
Description: Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
Study: NCT04204018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: * First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case.
Study: NCT02206516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Study: NCT00321451

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pseudo-desensitization procedure
Description: 4 biweekly outpatient visits with sleep psychologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 3 outpatient visits with study physician
Study: NCT00445185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Henogen HB vaccine
Description: Month 12, 24 and 36
Study: NCT02011048

Intervention type: PROCEDURE
Intervention: Endoscopic components separation
Description: Endoscopic components separation hernia repair
Study: NCT00445185

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix vaccine
Description: Month 12, 24 and 36
Study: NCT03788733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: 1 time a day for 8 weeks
Study: NCT00402467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 2.5mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 5mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 10 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: 30mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: 30mg bid
Study: NCT03636126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR + TACS
Description: TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
Study: NCT04688749

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical Impedence Spectroscopy DermaSense
Description: Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical Impedence Spectroscopy DermaSense
Description: Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
Study: NCT00519272

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
Study: NCT03449069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-AFP
Description: Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
Study: NCT00118872

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Description: Yogurt NOT containing the active LGG bacteria
Study: NCT03418636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Safe (Ssafe)
Description: Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
Study: NCT03981679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will also include samples of blood samples collected before colonoscopy
Study: NCT02047214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study: NCT05176236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictographic tracheostomy care handouts
Description: The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
Study: NCT02211248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assistance
Description: Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow up
Description: Assistance was effected by physician and nurse and consisted about adapting to the drug
Study: NCT03788733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: 1 time a day for 8 weeks
Study: NCT02806726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDesign 1.3-PRESBY treatment
Description: Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign 1.3 treatment
Description: Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
Study: NCT03289104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Wires
Description: Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
Study: NCT00080301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone + Capecitabine
Description: Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Study: NCT04389723

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Qualia Mind
Description: Multi-ingredient Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Qualia Mind
Description: Multi-ingredient Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Multi-ingredient Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Multi-ingredient Placebo
Study: NCT00377858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro mid mixture (MM)
Description: Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks